Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Regorafenib 40 MG Oral Tablet
DRUG
2 trials
Sponsors
Universitair Ziekenhuis Brussel
, Istituto Oncologico Veneto IRCCS
Conditions
Melanoma Stage III
Melanoma Stage IV
Meningioma, Malignant
Phase 2
A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma
NCT05370807
Universitair Ziekenhuis Brussel
Melanoma Stage III, Melanoma Stage IV
Start: 2022-10-03
End: 2025-03-31
Target: 48
Updated: 2023-10-24
Regorafenib for Recurrent Meningioma (MIRAGE Trial)
Recruiting
NCT06275919
Istituto Oncologico Veneto IRCCS
Meningioma, Malignant
Start: 2024-09-23
End: 2027-03-01
Target: 104
Updated: 2026-03-27
Related Papers
TIP-05. Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: the MIRAGE trial
Neuro-Oncology
2025-11-01
P13.14.A REGORAFENIB VERSUS LOCAL STANDARD OF CARE IN PATIENTS WITH GRADE 2-3 MENINGIOMA NO LONGER ELIGIBLE FOR LOCO-REGIONAL TREATMENTS: THE MIRAGE TRIAL
Neuro-Oncology
2025-10-01
Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).
2025-08-04
Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: The MIRAGE trial.
Journal of Clinical Oncology
2025-05-28
A phase 2 clinical trial of regorafenib in patients with advanced pretreated melanoma (RegoMel).
Journal of Clinical Oncology
2024-06-01